邱净英

个人简历

2006年毕业于沈阳药科大学，获理学学士学位，2012年毕业于贵州大学（贵州省中国科学院天然产物化学重点实验室），获理学博士学位，同年进入hg8868官网药物分析教研室任职。2020年于美国明尼苏达大学交流访学一年。近年来研究方向为抗病毒药物分子的设计、合成及生物活性研究，先后主持国家自然科学基金青年基金、江苏省自然科学基金青年基金、江苏省自然科学基金面上项目等科研项目。以第一或通讯作者在European Journal of Medicinal Chemistry、Bioorganic & Medicinal Chemistry等杂志发表SCI论文20余篇，申请专利4项（已授权2项）。主要承担研究生《药物光谱分析选论》以及药学、临床药学、药物制剂等本科专业《药物分析》、《分析化学》等课程的理论及实验教学。

承担科研课题

1. 国家自然科学基金青年基金项目，81703359，基于药效团融合的新型抗HBV药物的设计、合成及生物活性研究，2018-01至2020-12，19.9万元，主持；

2. 江苏省自然科学基金面上项目，BK20181151，具有双重作用机制的药效团融合型抗HBV化合物的设计、合成及生物活性研究，2018-07至2021-06，10万元，主持；

3. 江苏省自然科学基金青年基金项目，BK20140223，多靶点抗乙肝病毒药物的设计、合成及生物活性研究，2014-07至2017-07，20万元，主持；

4. 徐州市科技计划项目，靶向核心蛋白和TLR7/8的新型喹唑啉酮类化合物的设计、合成及抗HBV活性研究，KC21011，6万元，2021-09至2023-08，主持；

5. 徐州医学院优秀人才科研启动基金，新型苯基丙酰胺类化合物的设计、合成及抗HBV活性研究，2013.06-2016.06，10万元，主持。

近五年代表性论文、专著

1. Jingying Qiu^#, Yueting Zou^#, Shuqiong Li, Lihua Yang, Zibin Qiu, Fanyun Kong^*, Xiaoke Gu^*, Discovery of benzimidazole substituted 1, 2, 4-oxadiazole compounds as novel anti-HBV agents with TLR8-agonistic activities, European Journal of Medicinal Chemistry, 2022, 244, 114833.

2. Jingying Qiu^#, Qingqing Zhou^#,Yueting Zou, Shuqiong Li, Lihua Yang, Wang Chen, Jian Gao^**, Xiaoke Gu^*, Design and synthesis of novel quinazolinone derivatives as anti-HBV agents with TLR8 agonist effect, European Journal of Medicinal Chemistry, 2022, 231, 114159.

3. Jingying Qiu^#, Yueting Zou^#, Qingchuan Liu, Chunyu Jiang, Qingqing Zhou, Shuqiong Li, Wang Chen, Zheng Li, Xiaoke Gu^*, Synthesis and evaluation of novel quinazolinone derivatives as potential anti-HCC agents, Chemistry & Biodiversity, 2022, 19(2): e202100766.

4. Xiaoke Gu^#, Yinpeng Zhang^#, Yueting Zou, Xin Li, Mingyu Guan, Qingqing Zhou, Jingying Qiu^*, Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents, Bioorganic & Medicinal Chemistry, 2021, 29:115892.

5. Xiaoke Gu^{#, *}, Mingyu Guan^#, Chunyu Jiang, Qinghua Song, Xin Li, Nan Sun, Jing Chen, Jingying Qiu^*. Assessment of Thiosemicarbazone-Containing Compounds as Potential Antileukemia Agents against P-gp Overexpressing Drug Resistant K562/A02 Cells, Chemistry & Biodiversity, 2021, 18(2): e2000775.

6. Jingying Qiu^#, Qingqing Zhou^#, Yinpeng Zhang, Mingyu Guan, Xin Li, Yueting Zou, Xuan Huang, Yali Zhao, Wang Chen, Xiaoke Gu^*, Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents, European Journal of Medicinal Chemistry, 2020, 205:112581.

7. Xiaoke Gu^{#, *}, Xin Li^#, Mingyu Guan, Chunyu Jiang, Qinghua Song, Nan Sun, Yueting Zou, Qingqing Zhou, Jing Chen, Jingying Qiu^*, Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells, Bioorganic & Medicinal Chemistry Letters, 2020, 30(24): 127638.

8. Xiaoke Gu^{#, *}, Jing Chen^#, Yinpeng Zhang, Mingyu Guan, Xin Li, Qingqing Zhou, Qinghua Song, Jingying Qiu^*, Synthesis and assessment of phenylacrylamide derivatives as potential anti-oxidant and anti-inflammatory agents, European journal of medicinal chemistry, 2019, 180: 62-71.

9. Jingying Qiu^#, Wang Chen^#, Yinpeng Zhang, Qingqing Zhou, Jing Chen, Lihua Yang, Jian Gao^*, Xiaoke Gu^*, Daoquan Tang^*, Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors, European Journal of Medicinal Chemistry, 2019, 176: 41-49.

10. Xiaoke Gu^{#, *}, Yanfei Jiang^#, Jing Chen, Yinpeng Zhang, Mingyu Guan, Xin Li, Qingqing Zhou, Qian Lu, Jingying Qiu^*, Xiaoxing Yin^*, Synthesis and biological evaluation of bifendate derivatives bearing acrylamide moiety as novel antioxidant agents, European Journal of Medicinal Chemistry, 2019, 162: 59-69.

11. Jingying Qiu^#, Qineng Gong^#, Jian Gao, Wang Chen, Yinpeng Zhang, Xiaoke Gu^*, Daoquan Tang^*, Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors, European Journal of Medicinal Chemistry, 2018, 144: 424-434.

12. Jingying Qiu^#, Wang Chen^#, Yanfei Jiang, Jing Chen, Yinpeng Zhang, Xiaoke Gu^*, Assessment of a bifendate derivative bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent, MedChemComm, 2018, 9(11): 1826-1830.